Guilin Sanjin Of China Trades Well In IPO Try, First In China In 10 Months
This article was originally published in PharmAsia News
Executive Summary
China's Guilin Sanjin Pharmaceutical prompted such a response on the day of its initial public offering, the Shenzhen Stock Exchange suspended trading on the shares. Before the halt, the first trading in China since IPOs were suspended 10 months ago, Guilin Sanjin shares rose by 20 percent. Trading was suspended in the Guilin Sanjin IPO and another company for just 30 minutes under stock exchange rules. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.